Is tadalafil associated with macular edema or subretinal neovascularization?

Tadalafil and Retinal Complications: Evidence Review

No established causal association exists between tadalafil and macular edema or subretinal neovascularization based on current FDA labeling and clinical guidelines, though rare case reports describe reversible retinal changes including serous retinal detachment and photoreceptor alterations.

FDA-Approved Safety Profile

The FDA label for tadalafil documents specific ophthalmologic adverse events but does not list macular edema or subretinal neovascularization as recognized complications 1. Postmarketing surveillance has identified:

• Retinal vein occlusion (rare postmarketing report) 1
• Retinal artery occlusion (rare postmarketing report) 1
• Non-arteritic anterior ischemic optic neuropathy (NAION) - the most significant documented vision-threatening complication 1
• Transient color vision changes (blue/green discrimination) occurring in <0.1% of patients, consistent with PDE6 inhibition in retinal phototransduction 1

Importantly, the FDA label makes no mention of macular edema or choroidal neovascularization as adverse events 1.

Controlled Clinical Trial Evidence

A rigorous 6-month randomized controlled trial (n=244) evaluated daily tadalafil 5 mg versus sildenafil 50 mg versus placebo using standardized electroretinography (ERG) and comprehensive retinal assessments 2. This study found:

• No significant differences in ERG parameters between tadalafil, sildenafil, and placebo groups 2
• No treatment-related retinal toxicity detected 2
• No changes in visual acuity, color discrimination, visual fields, or intraocular pressure 2
• No anatomic retinal abnormalities identified 2

This represents the highest-quality prospective evidence directly addressing tadalafil's retinal safety profile.

Case Reports of Retinal Changes

Despite the reassuring controlled trial data, isolated case reports describe reversible retinal findings:

Serous Retinal Detachment

A 53-year-old male developed bilateral asymptomatic neurosensory retinal detachment while using tadalafil 3. Following drug discontinuation, subretinal fluid reabsorbed, though chronic OCT and visual field changes persisted 3. The proposed mechanism involves PDE5 inhibition causing choroidal vasodilatation, increased hydrostatic pressure, and subretinal exudation 3.

Photoreceptor Changes

One case documented reversible parafoveal photoreceptor damage with spectral-domain OCT showing hyperreflective IS-OS interface changes and pseudo-serous retinal detachment appearance 4. These findings completely resolved 2 months after tadalafil discontinuation 4.

Long-Term Vascular Changes

A prospective study (n=22) of patients taking tadalafil 20 mg on alternate days for 6 months after prostatectomy found 5:

• Statistically significant reduction in deep capillary plexus and choriocapillaris vessel density at 6 months 5
• Increased subfoveal choroidal thickness 5
• Increased ganglion cell complex thickness 5
• No changes in superficial capillary plexus, radial peripapillary capillaries, or foveal avascular zone 5

Critical Distinction: Macular Edema vs. Serous Detachment

The case reports describe serous retinal detachment (subretinal fluid accumulation), not macular edema (intraretinal fluid accumulation) 3, 4. These are distinct pathophysiologic entities:

• Macular edema involves intraretinal fluid from vascular leakage or inflammation, commonly seen in diabetic retinopathy, retinal vein occlusions, and uveitis 6
• Serous retinal detachment involves subretinal fluid accumulation from choroidal vascular changes or RPE dysfunction 3

Tadalafil does not appear in comprehensive reviews of drug-induced macular edema, which list thiazolidinediones, fingolimod, tamoxifen, taxanes, niacin, interferons, and prostaglandin analogs as causative agents 7.

Subretinal Neovascularization

No evidence links tadalafil to subretinal or choroidal neovascularization. Macular neovascularization results from increased VEGF synthesis due to localized ischemia and inflammation, typically in age-related macular degeneration, pathologic myopia, or inflammatory conditions 8. The mechanism of PDE5 inhibition (causing vasodilation) is fundamentally different from the ischemia-driven VEGF upregulation that triggers neovascularization 8.

Clinical Recommendations

For patients using tadalafil who develop visual symptoms:

1. Perform comprehensive dilated fundus examination with attention to subretinal fluid, not just intraretinal edema 3, 4
2. Obtain spectral-domain OCT to differentiate serous retinal detachment from true macular edema 4
3. Consider tadalafil discontinuation if unexplained subretinal fluid is present, as case reports show reversibility 3, 4
4. Evaluate for alternative causes including central serous chorioretinopathy, posterior uveitis, or retinal vein occlusion 1

Common pitfalls to avoid:

• Do not confuse serous retinal detachment with macular edema—they require different diagnostic and therapeutic approaches 3, 4
• Do not overlook tadalafil in the medication history when evaluating unexplained subretinal fluid 3
• Do not assume permanent damage—reported cases show complete or near-complete resolution after drug cessation 3, 4

Strength of Evidence Assessment

The evidence hierarchy strongly favors tadalafil safety:

• Highest quality: Prospective randomized controlled trial showing no retinal toxicity over 6 months 2
• FDA postmarketing surveillance: No listing of macular edema or neovascularization 1
• Lowest quality: Isolated case reports of reversible serous changes 3, 4

The weight of evidence does not support a clinically significant association between tadalafil and either macular edema or subretinal neovascularization. The rare case reports likely represent idiosyncratic responses in susceptible individuals rather than a class effect.